Results 31 to 40 of about 213,347 (314)

Thrombocytopenia as a Clinical Biomarker of Retinopathy of Prematurity

open access: yesFolia Medica Indonesiana, 2023
Highlights: • This is the first systematic review investigating thrombocytopenia and its association with retinopathy of prematurity. • Thrombocytopenia can be a useful clinical biomarker in retinopathy of prematurity screening, considering the quick,
I Wayan Eka Sutyawan   +4 more
doaj   +1 more source

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries

open access: yesHaematologica
Not available.
Guillaume Moulis   +21 more
doaj   +1 more source

Long-Term Outcome of Otherwise Healthy Individuals with Incidentally Discovered Borderline Thrombocytopenia.

open access: yes, 2006
BACKGROUND: The long-term outcome of individuals with mild degrees of thrombocytopenia is unknown. METHODS AND FINDINGS: In a prospective study conducted between August 1992 and December 2002, 260 apparently healthy individuals with incidentally ...
Sergio Amadori   +17 more
core   +1 more source

Prognostic value of thrombocytopenia during hospitalizations in intracerebral hemorrhage patients

open access: yesFrontiers in Neurology
BackgroundThe thrombocytopenia influences prognoses of critically ill patients. There are few studies exploring the prognostic value of thrombocytopenia among ICH patients.
Hao Feng   +4 more
doaj   +1 more source

Immune Thrombocytopenia [PDF]

open access: yesHematology, 2010
Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmune-mediated platelet destruction and impairment of thrombopoiesis. ITP may occur in the absence of an evident predisposing etiology (primary ITP) or secondary to a growing list of associated conditions (secondary ITP), and must be differentiated from ...
Adam, Cuker, Douglas B, Cines
openaire   +2 more sources

Profound thrombocytopenia after primary exposure to eptifibatide

open access: yes, 2010
Nicholas B Norgard, Brian T BadgleyUniversity at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USAAbstract: Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients ...
null Brian Badgley   +3 more
core   +1 more source

Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. [PDF]

open access: yes, 2008
\ud \ud Studies of antiretroviral therapy (ART) programs in Africa have shown high initial mortality. Factors contributing to this high mortality are poorly described.
Matee, Mecky I.   +36 more
core   +1 more source

The wandering spleen: an unusual case of thrombocytopenia

open access: yes, 2011
Curtis Mirkes, George Nguyen, Christian CableDepartment of Internal Medicine, Division of Hematology and Oncology, Texas A&M Health Science Center, College of Medicine, Scott & White Healthcare, Temple, TX, USAAbstract: Thrombocytopenia ...
Nguyen G   +4 more
core   +1 more source

The Incidence of Thrombocytopenia and Its Association with Mortality in Patients with Sepsis Followed in Intensive Care Unit

open access: yes, 2023
Aim:Thrombocytopenia is common in intensive care units (ICU) and is associated with high mortality. The aim of this study aimed to determine the incidence of thrombocytopenia in patients diagnosed with sepsis and its relationship with mortality and ...
Hatice Eyiol   +6 more
core   +1 more source

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer

open access: yesCase Reports in Oncology, 2021
Severe thrombocytopenia is a rare adverse event of panitumumab. Here, we report the first patient with metastatic colorectal cancer who developed severe thrombocytopenia, diagnosed as panitumumab-associated drug-induced immune thrombocytopenia (DITP).
Shigemasa Takamizawa   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy